A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels
Background: Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduces low-density lipoprotein cholesterol (LDL-C) levels and decreases the incidence of major ischaemic events in clinical trials. However, less is known about the efficacy of PCSK9 inhibition in clinical p...
Main Authors: | Maria K. Svensson, Stefan James, Annica Ravn-Fischer, Guillermo Villa, Lovisa Schalin, Thomas Cars, Stefan Gustafsson, Emil Hagström |
---|---|
Format: | Article |
Language: | English |
Published: |
Upsala Medical Society
2024-01-01
|
Series: | Upsala Journal of Medical Sciences |
Subjects: | |
Online Access: | https://ujms.net/index.php/ujms/article/view/9618/16831 |
Similar Items
-
Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial
by: Hong Tan, et al.
Published: (2023-02-01) -
Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
by: Federica Fogacci, et al.
Published: (2021-08-01) -
Sex X Time Interactions in Lp(a) and LDL-C Response to Evolocumab
by: Federica Fogacci, et al.
Published: (2023-12-01) -
Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01) -
Adverse Reactions to Evolocumab: Analysis of Real-World Data from EudraVigilance
by: Fabrizio Calapai, et al.
Published: (2024-03-01)